Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
about
Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.Herb-drug pharmacokinetic interactions reviewed.Pharmacokinetic drug interactions involving Ginkgo biloba.Drug interactions with phytotherapeutics in oncology.PharmGKB summary: voriconazole pathway, pharmacokinetics.CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
P2860
Q33604138-E26D7305-8E7A-4EAE-B7F1-869BD5DDB597Q33849298-AFA2F4F8-1D95-45AD-83DE-59F9E687DB71Q35725540-49135318-42F2-4A4E-A130-17F16120C1F7Q35904433-2C6543FA-E7B9-45AA-A452-9B89405AD533Q35936943-681FB64E-5451-4D58-8DFB-5662ECFE10B8Q36273788-9D8A1BFB-7DA2-4FBA-B890-0C13F6833DFAQ36608562-5BE6A08A-CF9D-40B3-8D6C-8F218E2C9442Q36673940-75140DAB-369A-4DD0-AF80-7F8D3CD71DF0Q36900535-ED2ABD02-EF8B-4209-B940-68D3452356D8Q37808478-0D8251E7-5ACA-41E5-86D0-46EAC4DF97C3Q38122439-44CE59A5-9DCC-40BA-A4B2-D9B53F071254Q38175476-D98115B8-C9CC-4D94-A69D-2ACF4052A8A2Q38918175-45E8E7C8-0B9A-429C-91C7-CAB36F35C51FQ51631938-96E419DC-314B-4152-955C-311D18CAF4F4
P2860
Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@en
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@nl
type
label
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@en
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@nl
prefLabel
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@en
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@nl
P2093
P2860
P356
P1476
Lack of effect of Ginkgo bilob ...... or and extensive metabolizers.
@en
P2093
Dong-sheng Ou-yang
He-Ping Lei
Hong-Hao Zhou
Lian-Sheng Wang
Yi-Jing He
P2860
P304
P356
10.1345/APH.1L537
P407
P577
2009-03-18T00:00:00Z